Login to Your Account



To Develop Gut-Safe Pain Drug

AstraZeneca, Pozen Entering PN Deal Worth Up To $375M

By Randall Osborne


Thursday, August 3, 2006
Once-hurting Pozen Inc. got whopping relief from AstraZeneca plc in the form of a potential $375 million deal, with $40 million up front, to develop fixed-dose combinations of naproxen and AstraZeneca's esomeprazole for chronic pain. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription